PMC:7600245 / 21186-21373 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T96","span":{"begin":25,"end":30},"obj":"Body_part"}],"attributes":[{"id":"A96","pred":"fma_id","subj":"T96","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"f targeting the infected cells, and intracellular half-life. It also decreases the potential renal toxicity of the monophosphate intermediate. Tenofovir alafenamide was first approved in "}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T197","span":{"begin":25,"end":30},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"f targeting the infected cells, and intracellular half-life. It also decreases the potential renal toxicity of the monophosphate intermediate. Tenofovir alafenamide was first approved in "}

{"project":"LitCovid-sentences","denotations":[{"id":"T155","span":{"begin":61,"end":142},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"f targeting the infected cells, and intracellular half-life. It also decreases the potential renal toxicity of the monophosphate intermediate. Tenofovir alafenamide was first approved in "}

{"project":"LitCovid-PubTator","denotations":[{"id":"568","span":{"begin":115,"end":128},"obj":"Chemical"},{"id":"569","span":{"begin":143,"end":164},"obj":"Chemical"},{"id":"581","span":{"begin":16,"end":24},"obj":"Disease"},{"id":"582","span":{"begin":93,"end":107},"obj":"Disease"}],"attributes":[{"id":"A569","pred":"tao:has_database_id","subj":"569","obj":"MESH:C442442"},{"id":"A581","pred":"tao:has_database_id","subj":"581","obj":"MESH:D007239"},{"id":"A582","pred":"tao:has_database_id","subj":"582","obj":"MESH:D007674"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"f targeting the infected cells, and intracellular half-life. It also decreases the potential renal toxicity of the monophosphate intermediate. Tenofovir alafenamide was first approved in "}